Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise
I'm PortAI, I can summarize articles.
Zai Lab's new drug application for KarXT, aimed at treating schizophrenia in adults, has been accepted by China's National Medical Products Administration. The application is supported by results from various studies, including a phase 1 pharmacokinetics study and a phase 3 study in China. Following the announcement, Zai Lab's shares rose by 2.1%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments